Please login to the form below
asthma treatment
This page shows the latest asthma treatment news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca’s severe asthma treatment approved in EU for self-administration
pen the first and only severe asthma biologic approved in the EU with no phenotype of biomarker limitations. ... treatment of severe asthma.
Latest news
-
AstraZeneca and Avillion’s asthma rescue treatment granted FDA approval
The approval of Airsupra means that for the first time, adults with asthma in the US have a rescue treatment to manage both their symptoms and the inflammatory nature of their ... Patients are at risk of severe exacerbations regardless of their disease
-
AZ and Avillion’s asthma rescue treatment recommended by FDA Advisory Committee
Drugs Advisory Committee (PADAC) for the treatment of asthma in patients aged 18 years and older, the company announced. ... Patients with asthma are at risk of severe exacerbations regardless of their disease severity, adherence to treatment or level of
-
AstraZeneca’s Tezspire receives MHRA approval as add-on treatment for severe asthma
use as an add-on maintenance treatment for patients 12 years and older with severe asthma, the company announced. ... It has been approved in the US and other countries for the treatment of severe asthma, and regulatory reviews are ongoing in additional
-
AstraZeneca’s Tezspire receives EC approval as severe asthma add-on treatment
AstraZeneca’s (AZ) Tezspire (tezepelumab) has been approved by the European Commission (EC) for use as an add-on maintenance treatment in patients 12 years and older with severe asthma, the ... of severe asthma, and regulatory reviews are ongoing in
-
Sanofi and Regeneron share positive data for asthma drug
age group with moderate-to-severe asthma and evidence of type 2 inflammation. ... safety profile of long-term Dupixent – which is indicated for the treatment of uncontrolled moderate-to-severe asthma with an oeosinophilic phenotype or oral
More from news
Approximately 1 fully matching, plus 148 partially matching documents found.
Latest Intelligence
-
Integrating digital biomarkers into precision medicine
Such monitoring could also allow for early prediction of treatment success, eg in a study to evaluate asthma treatment outcomes. ... For example, monitoring heart rate and rhythm data in patients receiving post-treatment for myocardial infarction (MI) to
-
Allergies and asthma
AIT with birch or grass pollen had a long-lasting preventive effect on asthma, up to seven years after the treatment was stopped. ... This evidence-based data demonstrates the need to manage allergies and asthma prenatally, as early treatment already
-
Pharma deals in July 2015
Firstly the divestment for up to $300m to Genzyme of Caprelsa (vandetanib), an orphan drug treatment for thyroid carcinoma. ... In Japan, AZ paid $45m for an option with Kyowa Hakko Kirin to commercialise benralizumab (currently in phase III for
-
Pharma deals during July 2014
Underscoring its strategy in focusing the business in the core areas, in July Baxter also announced the acquisition of AesRx, a private US company developing a phase II stage prophylactic treatment ... The acquisition of Almirall's respiratory business
-
Interview: Georg Toufar, Mundipharma
Treatments successfully brought to market in this way include asthma treatment Flutiform, created by Skye Pharma, and restless legs syndrome treatment Targin.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
Time for a new language for asthma?
Despite the global advances made in the treatment for asthma, many studies have shown that asthma remains uncontrolled for a large proportion of patients, when assessed according to international guidelines. ... A comprehensive market research study has
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- 2023 PM Society Awards – winners announced
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- FDA external report recommends actions to address US opioid crisis
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Inizio appoints Stefanie Christmas as global head of DE&I
- Rare diseases: not so rare after all
- Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis
- Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
- Havas Health & You appoints Alex Okada as chief creative officer of Havas Lynx Group
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
